ArticleFrontiers in pharmacology2026
Immune profiling in trigeminal neuralgia reveals altered cytokine and chemokine signatures in cerebrospinal fluid and serum.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neural Expression of IL-16 Mediates Neuropathic Pain after Sciatic Injury in Mice.Molecular neurobiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Trigeminal neuralgia (TN) is a debilitating neuropathic pain disorder traditionally attributed to neurovascular compression; however, this mechanism does not fully explain the marked clinical heterogeneity or persistent pain observed in a subset of patients. Increasing evidence suggests that central neuroinflammatory processes contribute to neuropathic pain, but immune profiles in the cerebrospinal fluid (CSF) and serum of patients with TN remain poorly characterized. Methods: We conducted a single-center cross-sectional study including 14 patients with TN and 19 non-pain controls. CSF samples were obtained from 14 TN patients and 10 controls, while serum samples were available from 10 TN patients and 9 controls. Concentrations of a broad panel of cytokines, chemokines, and growth factors were measured using multiplex immunoassays. Group comparisons were performed using non-parametric statistical tests, with false discovery rate correction for multiple comparisons. Results: Patients with TN reported severe pain (median numerical rating scale score: 8), whereas controls reported no pain. Demographic characteristics, including age, sex, and body mass index, were comparable between groups. Compared with controls, CSF from TN patients showed significantly elevated levels of multiple pro-inflammatory cytokines and chemokines, including TNF-α TNF-β, IL-1β, IL-9, IL-16, IL-17, IL-18, IFN-γ, CCL5, CXCL12, and macrophage migration inhibitory factor (MIF) (all false discovery rate-adjusted p < 0.05). In contrast, vascular endothelial growth factor (VEGF) concentrations were significantly reduced in the CSF of TN patients. No corresponding inflammatory alterations were observed in serum samples. Discussion: TN is associated with a distinct CSF immune signature characterized by elevated pro-inflammatory mediators and altered growth factor profiles. These findings support the involvement of central neuroimmune mechanisms in the pathophysiology of TN and highlight the potential value of CSF biomarkers for improving mechanistic understanding and identifying novel therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.